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Gangliosides from cell cultures established from melanocytic lesions, representing different stages of mela- 
noma tumor progression, were analyzed by chemical and immunological means on thin-layer chromato- 
grams. The GD2 ganglioside and N-acetylgalactosaminyl transferase, which catalyzes the biosynthesis of 
GD2 from its precursor GD3, were detected in cultures established from advanced primary and metastatic 
melanomas, but not in cultures of normal melanocytes. Immunohistochemical studies on tissue sections 
from all progression stages confirmed GD2 expression only in these advanced lesions. A distinct biochemical 
event thus coincides with the onset of faster growth and acquisition of metastatic competence in human 
melanoma tumor progression 
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1. INTRODUCTION are all rich in gangliosides, which are synthesized 
Human melanoma provides one of the best 
tumor progression models available, because the 
early developing lesions can be studied with 
relative ease as they develop in the skin. The le- 
sional steps that may culminate in metastatic 
melanoma are: (i) the common acquired nevus; (ii) 
melanocytic nevus; (iii) dysplastic nevus; (iv) 
primary cancer without competence for metastasis 
(radial growth phase); (v) primary cancer with 
metastatic competence and accelerated prolifera- 
tion (vertical growth phase); and (vi) metastatic 
melanoma [ 11. Cells from the melanocytic system 
Abbreviations: Abbreviations for gangliosides follow 
the Svennerholm nomenclature, L. Svennerholm, 1963; 
chromatographic separation of human brain 
gangliosides (J. Neurochem. 10, 613) and otherwise the 
ILJPAC-IUB Commission on Biochemical Nomen- 
clature 1977 (Eur. J. Biochem. 79, 3512) were followed; 
mAb, monoclonal antibody; TLC, thin-layer chro- 
matography 
by stepwise addition of activated sugars from the 
common precursor lactosylceramide (GalPl 4 
4GlcCer). Fig.1 demonstrates the synthesis of the 
five major melanoma-associated gangliosides 
(GM3, GM2, GD3, 9-O-acetyl GD3, and GD2) 
[2-l 51. Using monoclonal antibodies [ 161 against 
melanoma gangliosides [7,8] to detect differences 
in ganglioside expression during tumor progression 
[ 1,17,18], we provide evidence that biosynthesis of 
ganglioside GD2 (NeuNAccu2+8NeuNAccu2+ 
3Ga1(4+ l,&GalNAc)fll+4Gl@l-+ 1Cer) from its 
precursor ganglioside GD3 (NeuNAm2+8Neu- 
NAccu2+3Gal,B1+4Glcfl1-+4Cer) coincides with 
an accelerated growth rate and the acquisition of 
metastatic competence in the progression of 
melanoma. 
2. MATERIALS AND METHODS 
2.1. Cells and monoclonal antibodies (mAbs) 
Melanocytic, nevic and fibroblastic cell cultures 
Tumor progression Melanocyte 
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Fig. 1. Schematic presentation for biosynthesis of major 
ganglioside species in the melanocytic system. 
and primary and metastatic cell lines as well as 
hybridomas were established and maintained as 
described [17,18]. 
2.2. Glycolipid fractions and thin-layer 
chromatography 
Total acid glycolipid fractions were obtained as 
described [7]. Approx. 30 ,ug of each fraction were 
applied per lane to glass-backed HPTLC plates 
(Merck/Bodman, Gibbstown, NJ) relative to the 
amount of protein. The resorcinol reagent was 
used for detection [19]. 
2.3. Chromatogram binding assay 
Identical amounts of the same fractions as above 
were applied onto alumina-backed HPTLC plates 
(Merck/Bodman, Gibbstown, NJ) to perform the 
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assay as described [7,20,21]. For detection lz51- 
labeled goat anti-mouse F(ab’)z (Capell, Wor- 
thington, PA) was used at 1500 cpm/pl. Primary 
antibodies were used as undiluted hybridoma 
culture supernatants, and autoradiograms 
developed using XAR-5 film (Eastman/Kodak, 
Rochester, NY) for 20 h at -70°C. 
2.4. Glycosyltransferase assay 
The assay was performed essentially as described 
[22] and repeated three times with each cell line, 
with identical results. 10 nmol UDP- 
[1-14C]GalNAc (Amersham, Arlington, IL) and 
40 pg GD3, purified and characterized as described 
[7], were added to microsomal preparations cor- 
responding to 1 mg protein. After incubation at 
37°C for 3 h, the lipids were extracted and half the 
extract used for TLC. For autoradiography, film 
was exposed to the thin-layer chromatogram for 
20 h at -70°C. 
2.5. Immunohistochemistry 
Immunohistochemistry was performed as 
described [8] on frozen sections by the peroxidase 
anti-peroxidase technique (Ortho Phar- 
maceuticals, Raritan, NJ). Previous studies [8], us- 
ing the more sensitive avidin-biotin 
immunoperoxidase methods, revealed reactivity in 
dysplastic nevi and radial growth phase 
melanomas. Here these lesions and normal 
melanocytes were uniformly negative. Reactivity 
was observed in the same lesions with other mAbs, 
including some that bind GD3 ganglioside. 
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Fig.2. Thin-layer chromatograms of total ganglioside fractions obtained from cultured cells obtained after 
chromatography in chloroform/methanol/0.2% CaClz in Hz0 (60 : 40: 9, v/v). Gangliosides were detected with 
resorcinol [ 191. Fractions were obtained from cultures of (lanes): fibroblasts (l-3); melanocytes (4-9); dysplastic nevus 
(10); congenital nevus (11); radial growth phase melanoma (12); vertical growth phase and metastatic melanoma 
(13-23); total human brain ganglioside fraction (24). Arrows indicate Rf values for gangliosides. 
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3. RESULTS AND DISCUSSION 
Fig.2 shows thin-layer chromatograms of total 
ganglioside extracts from cell cultures established 
from tissue at different stages in the progression of 
melanoma. This assay reveals not only the 
presence of particular gangliosides, and therefore 
their biosynthesis, but also gives information 
regarding their expression, because the amount ex- 
pressed on the cell surface of gangliosides GD2 and 
GD3 correlates with the extractable amount of 
these gangliosides in the cell [8]. Lanes l-3 show 
gangliosides from cultured fibroblasts (negative 
controls) established from the same normal 
foreskins that were the source of the melanocytes 
for the cultures shown in lanes 4-6. A stable pat- 
tern of ganglioside expression was observed in nor- 
mal fibroblasts (lanes l-3) and normal 
melanocytes (lanes 4-9 and six additional normal 
melanocyte cultures, not shown). GM3 was the 
major ganglioside in fibroblasts, and GM3 and 
CD3 were the major species in melanocytes, with 
GD3 predominating. The latter finding contrasts 
somewhat with that of Carubia et al. [13], who 
reported that GM3 was the predominant species in 
cultured melanocytes. Thus, ganglioside biosyn- 
thesis in melanocyte cultures is halted at the GM3 
and CD3 stages (see fig.l), in contrast to human 
brain and fibroblasts, where extension of the 
neutral carbohydrate chain in GM3 and GD3 with 
Gaul -+3GalNAc/31-+4- results in brain-type 
ganglioside biosynthesis [ 14,151. 
Chromatograms of gangliosides from cultures 
of vertical growth phase and metastatic melanoma 
lesions (fig.2, lanes 13-23) illustrate the aberrant 
biosynthesis of gangliosides at the later stages of 
melanoma progression. All of the melanoma- 
associated ganglioside antigens were present, but 
the relative amounts of each differed in different 
cultures (lanes 13-23), with GD3 being the most 
abundant species. 
The same ganglioside extracts were also tested in 
a chromatogram binding assay with mAbs that 
detect melanoma-associated gangliosides (fig.3). 
Using antibody ME361 (row l), which detects GD2 
as the major antigen and cross-reacts to a lesser ex- 
tent with GD3 [7], GD2 was detected in abundance 
in the extracts of cell cultures established from ver- 
tical growth phase and metastatic melanoma le- 
sions but was not detected in cultures from lesions 
prior to this stage in progression. Antibody ME3 11 
(row 2), which detects 9-O-acetyl GD3 [7], revealed 
gradually increasing amounts of that ganglioside in 
the stages of progression from normal melanocytes 
to metastatic melanoma. Antibody ME24 (row 3), 
which detects GD3 as the major antigen and reacts 
slightly with GD2 (unpublished), detected GD3 in 
all cell extracts and GD2 in extracts of some 
cultures from advanced lesions (lanes 13-16, 
18-20, 23). Among earlier lesions, only that 
established from a congenital nevus (fig.3, row 1, 
lane ll), a lesion that does not fit into the tumor 
progression scheme (no. l), had detectable 
amounts of the GD2 ganglioside. The onset of 
GD2 expression can therefore be localized between 
the steps defined as radial growth phase and ver- 
tical growth phase melanoma, thus coinciding in 
time with a higher proliferation rate and the ac- 
quisition for metastasis. 
Results of immunoperoxidase analyses, using 
antibody ME361 on frozen sections, are consistent 
with this conclusion and also indicate that the 
finding is relevant in vivo by showing intense stain- 
ing in 6/7 vertical growth phase and 19123 meta- 
static melanoma sections, as compared with 
staining of melanocytes in O/l0 sections of normal 
skin, O/18 compound and/or dysplastic nevi sec- 
tions, and l/10 radial growth phase melanoma sec- 
tions. The weak occasional binding observed in 
early lesions probably reflected the presence of 
GD3, the ganglioside expressed throughout mela- 
noma progression and in fibroblasts, as deter- 
mined by antibodies ME361 and ME24 (fig.3, rows 
1 and 3, respectively). 
The biosynthesis of carbohydrate chains is 
catalyzed by glycosyltransferases [ 14,151. Syn- 
thesis requires availability of an activated sugar, 
which in the case of GD2 biosynthesis is UDP- 
GalNAc (fig.l), as well as precursor glycolipid. 
The turnover rate of these components is impor- 
tant in the final balance of ganglioside biosyn- 
thesis. Our observations (fig.2, lanes 13-23) 
indicate that abnormalities in biosynthesis occur 
randomly in the advanced stages of melanoma. To 
determine the basis for elevated GD2 biosynthesis, 
we studied the glycosyltransferase activity in 
microsomal preparations of cell cultures from ver- 
tical growth phase and metastatic lesions relative 
to that of cultured melanocytes. In the assay used, 
both UDP-[1-14C]GalNAc and pure precursor 
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Fig.3. Autoradiograms of chromatograms identical to those in fig.2 but reacted with mAbs. Rows: 1, ME361, detecting 
GD2 and, to a lesser extent, GD3 [7]; 2, ME31 1, detecting 9-0-acetyl GD3 [6]; 3, ME24, detecting CD3 and, to a lesser 
extent, GD2 (unpublished). 
GD3 ganglioside were present in excess, so that 
GD2 biosynthesis, i.e., addition of GalNAc@l+4- 
to CD3 (see fig. l), over that generated from possi- 
ble endogenous substrates could be followed. 
Following TLC of the 14C-labeled products ex- 
tracted (fig.4), bands were observed at the Rf value 
of GD2 in extracts of microsomal preparations ob- 
tained from vertical growth phase and metastatic 
melanoma cells (lower bar, lanes 1 and 2, respec- 
tively), but not in extracts of cultured melanocytes 
(lane 3). A control in which a microsomal prepara- 
tion from a vertical growth phase-derived cell 
culture was assayed without GD3 precursor was 
also negative (lane 4). The band with Rf value of 
GM2 (lane 1, upper bar) was not a biosynthetic 
product from endogenous substrate, because 14C- 
20 
labeled GM2 was not recovered when GM3 
ganglioside was used as substrate in the assay (not 
shown). This band probably reflects sialidase ac- 
tivity which produced GM2 from 14C-labeled GD2. 
Because the induced enzymatic activity only 
catalyzes the formation of GD2 from GD3, and 
not that of GM2 from GM3 (fig. l), it appears that 
the CD3 ganglioside is highly preferred as 
substrate. 
The relationship, if any, between the onset of 
GD2 biosynthesis and the concomitant increase in 
proliferation that characterizes vertical growth 
phase melanoma lesions is unclear, although 
gangliosides are known to influence the affinity 
and phosphorylation of growth factor receptors 
[23,24]. In particular, Bremer et al. [24] have 
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Fig.4. Autoradiogram of the thin-layer chromatograms 
of the reaction products of a glycosyltransferase assay. 
Products of extracts of vertical growth phase melanoma 
cell line, metastatic melanoma cell line, and cultured 
melanocytes, all incubated with GD3 ganglioside, are 
seen in lanes 1, 2, and 3, respectively. Lane 4 contains 
products from a vertical growth phase melanoma cell 
line extract incubated as in lane 1 but without GD3 
substrate. The bars on the left indicate the Rf values for 
GD2 (lower) and GM2 (upper). 
demonstrated that gangliosides added exogenously 
to EGF-receptor rich A431 cells are incorporated 
into the cell membrane. They have suggested a 
‘lateral’ mode of interaction between ganglioside 
and growth factor receptor that results in increased 
affinity and decreased phosphorylation of the 
receptor. Enhanced EGF-receptor expression has 
been correlated with trisomy of chromosome 7 in 
advanced melanoma [25]. In view of our present 
results, analysis of GD2 as it interacts with the 
EGF receptor in melanoma seems warranted. 
Similarly, analysis of the human immune response 
to GD2 ganglioside, which has been described as 
immunogenic in humans [9-121, could now take 
into consideration the abrupt expression of this an- 
tigen at the vertical growth phase stage, which has 
been correlated with disappearance of the T cell in- 
filtrate known to be present at the earlier stages of 
melanoma progression [ 11. 
Finally, the GD2 ganglioside has been im- 
plicated in the attachment of melanoma cells to 
solid substrata [26], which makes out observation 
that the induction of GD2 ganglioside expression 
in vertical growth phase melanoma, coinciding 
with the acquisition for metastasis, more in- 
teresting, since taken together they implicate a 
possible role of this ganglioside in the in vivo 
metastatic process. 
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